 Kathleen Dorris
Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 6 | 2026 | 176 | 2.030 |
Why?
| | Infratentorial Neoplasms | 4 | 2026 | 71 | 1.950 |
Why?
| | Brain Neoplasms | 9 | 2022 | 1318 | 1.340 |
Why?
| | Glioma | 4 | 2021 | 425 | 1.060 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.930 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2026 | 161 | 0.900 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1953 | 0.800 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2026 | 1137 | 0.600 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 2192 | 0.510 |
Why?
| | Spinal Neoplasms | 1 | 2017 | 36 | 0.510 |
Why?
| | Ganglioglioma | 1 | 2017 | 34 | 0.500 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 62 | 0.490 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2016 | 52 | 0.490 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 431 | 0.400 |
Why?
| | Histones | 1 | 2017 | 668 | 0.340 |
Why?
| | Survival Rate | 3 | 2026 | 2088 | 0.310 |
Why?
| | Prognosis | 5 | 2026 | 4278 | 0.310 |
Why?
| | Child | 13 | 2026 | 22537 | 0.290 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 78 | 0.280 |
Why?
| | Injections, Spinal | 1 | 2026 | 120 | 0.240 |
Why?
| | Follow-Up Studies | 3 | 2026 | 5389 | 0.220 |
Why?
| | Chromosomes | 1 | 2024 | 108 | 0.200 |
Why?
| | Fluorouracil | 1 | 2024 | 235 | 0.190 |
Why?
| | Neoplasm Grading | 2 | 2021 | 307 | 0.190 |
Why?
| | Pineal Gland | 1 | 2022 | 15 | 0.190 |
Why?
| | Pinealoma | 1 | 2022 | 9 | 0.190 |
Why?
| | Germinoma | 1 | 2022 | 10 | 0.190 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.180 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 17 | 0.180 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 191 | 0.180 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.170 |
Why?
| | Hydrocephalus | 1 | 2022 | 111 | 0.170 |
Why?
| | Neoplasms | 1 | 2016 | 2870 | 0.170 |
Why?
| | Infant | 3 | 2026 | 10022 | 0.160 |
Why?
| | Vinblastine | 1 | 2020 | 75 | 0.160 |
Why?
| | Carboplatin | 1 | 2020 | 160 | 0.150 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 14 | 0.150 |
Why?
| | Child, Preschool | 3 | 2026 | 11774 | 0.150 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 11 | 0.150 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 237 | 0.140 |
Why?
| | Craniopharyngioma | 1 | 2019 | 77 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1264 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 210 | 0.130 |
Why?
| | Humans | 14 | 2026 | 144261 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 190 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 162 | 0.120 |
Why?
| | Neuroimaging | 1 | 2019 | 289 | 0.120 |
Why?
| | Radiotherapy | 1 | 2017 | 206 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1455 | 0.120 |
Why?
| | Treatment Outcome | 2 | 2024 | 11643 | 0.120 |
Why?
| | Safety | 1 | 2016 | 355 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2018 | 1782 | 0.100 |
Why?
| | Male | 7 | 2026 | 72035 | 0.100 |
Why?
| | Adolescent | 4 | 2022 | 22281 | 0.100 |
Why?
| | Cell Line, Tumor | 2 | 2018 | 3539 | 0.090 |
Why?
| | Female | 6 | 2026 | 77976 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4556 | 0.070 |
Why?
| | Mice | 2 | 2024 | 18329 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2020 | 6424 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2022 | 17009 | 0.070 |
Why?
| | Mutation | 1 | 2017 | 4085 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 1025 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 13990 | 0.050 |
Why?
| | Animals | 2 | 2024 | 38030 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 183 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 556 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 919 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 22 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Overweight | 1 | 2022 | 606 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 123 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 928 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 681 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 321 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 10699 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1044 | 0.030 |
Why?
| | Algorithms | 1 | 2022 | 1834 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 582 | 0.020 |
Why?
| | Body Mass Index | 1 | 2022 | 2420 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2494 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2017 | 748 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2430 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5935 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1497 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1739 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2730 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 3057 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3857 | 0.020 |
Why?
|
|
Dorris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|